Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a day
admin First the good news: Pfizer Inc. and Germany-based partner BioNTech SE said updated trial data…
Read Moremedical treatments
Moderna stock falls after earnings miss by a wide margin and company cuts sales outlook by up to $3 billion
Moderna Inc. shares moved lower Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter…
Read MoreWeekly tally of COVID cases and deaths continues to fall; Moderna lowers vaccine-sales outlook by as much as $3 billion
The global tally of COVID-19 cases fell 17% in the week through Oct. 30 from…
Read MoreWeekly tally of COVID cases and deaths continues to fall; Moderna lowers vaccine-sales outlook by as much as $3 billion
The global tally of COVID-19 cases fell 17% in the week through Oct. 30 from…
Read MoreLilly’s new diabetes drug doubled sales expectations. It may also be used to treat obesity
Eli Lilly & Co. Inc.’s LLY, -2.57% steady transformation into a developer of both cutting-edge…
Read MoreHospitalizations on the rise in New York City as new COVID strains spread rapidly
Hospitalizations are rising again in New York City with the spread of new COVID-19 subvariants…
Read MoreHospitalizations on the rise in New York City as new COVID strains spread rapidly
Hospitalizations are rising again in New York City with the spread of new COVID-19 subvariants…
Read MoreDialysis company DaVita stock suffering worst day in 22 years after big profit miss, disappointing outlook
Shares of DaVita Inc. plummeted in active trading Friday, toward their worst performance in more…
Read MoreSanofi posts higher sales but $2.07 billion net profit misses forecasts
Sanofi SA on Friday posted higher sales for the third quarter, though net profit declined…
Read More
Wall Street is being nicer on earnings as vaccine makers, fintech reports near
With a downcast earnings season passing the halfway mark, results from financial-technology and vaccine makers…
Read More